Craig Lindsley, Ph.D., co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been honored by the University of Kansas with the 2018 Edward E. Smissman Lectureship for his outstanding contributions to the fields of medicinal chemistry and molecular pharmacology.

An enzyme in the gut – NAPE-PLD – is required for the action of signaling molecules that reduce food intake and weight gain.

Elevated levels of the factor G-CSF appear to promote the development of aggressive pancreatic cancer, suggesting a new therapeutic approach for this devastating disease.

Vanderbilt investigators have discovered that oxidative damage may play an important role in the development of a rare cholesterol synthesis disease and in the behavioral changes of autism spectrum disorders.

Vanderbilt researchers have found that red blood cell membrane fatty acid content is associated with risk of having colorectal adenomas, with omega-6 fatty acids increasing and omega-3 fatty acids decreasing risk.

A group of nationally recognized medical information and data management experts has recommended the development of new knowledge software applications that work alongside electronic health record systems (EHRs) to help practicing oncologists access and use the latest genomic information to assist in the treatment of cancer patients.

Based on findings from Vanderbilt investigators and others, clinical trials of estrogen inhibition for pulmonary arterial hypertension have recently been approved and funded by the National Institutes of Health.